AR049940A1 - Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor - Google Patents
Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremorInfo
- Publication number
- AR049940A1 AR049940A1 ARP050102604A ARP050102604A AR049940A1 AR 049940 A1 AR049940 A1 AR 049940A1 AR P050102604 A ARP050102604 A AR P050102604A AR P050102604 A ARP050102604 A AR P050102604A AR 049940 A1 AR049940 A1 AR 049940A1
- Authority
- AR
- Argentina
- Prior art keywords
- azethyl
- lower alkyl
- heterocyclyl
- aryl
- group
- Prior art date
Links
- 206010044565 Tremor Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000006517 essential tremor Diseases 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 25
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 12
- -1 methylpyrrolyl Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 125000001425 triazolyl group Chemical group 0.000 abstract 2
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003838 furazanyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000005956 isoquinolyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000005936 piperidyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58208404P | 2004-06-24 | 2004-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049940A1 true AR049940A1 (es) | 2006-09-13 |
Family
ID=34970895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102604A AR049940A1 (es) | 2004-06-24 | 2005-06-24 | Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7427601B2 (enExample) |
| EP (1) | EP1758606A1 (enExample) |
| JP (1) | JP5038892B2 (enExample) |
| KR (1) | KR20070034477A (enExample) |
| CN (1) | CN1964733B (enExample) |
| AR (1) | AR049940A1 (enExample) |
| AU (1) | AU2005256468B2 (enExample) |
| BR (1) | BRPI0512622A (enExample) |
| CA (1) | CA2566301C (enExample) |
| EA (1) | EA013592B1 (enExample) |
| IL (1) | IL179732A0 (enExample) |
| MX (1) | MXPA06015010A (enExample) |
| MY (1) | MY146509A (enExample) |
| NO (1) | NO20070423L (enExample) |
| NZ (1) | NZ551207A (enExample) |
| TW (1) | TWI361693B (enExample) |
| UA (1) | UA88166C2 (enExample) |
| WO (1) | WO2006000397A1 (enExample) |
| ZA (1) | ZA200609021B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1243262E (pt) * | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| ES2185606T3 (es) * | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| ATE428413T1 (de) * | 2003-12-02 | 2009-05-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (en) * | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| CN1950101B (zh) | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| EP1781276B1 (en) * | 2004-08-27 | 2010-06-23 | UCB Pharma GmbH | Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US7902401B2 (en) * | 2006-12-14 | 2011-03-08 | Nps Pharmaceuticals, Inc. | Fluorinated compounds |
| PT2462990E (pt) | 2006-06-15 | 2014-04-02 | Ucb Pharma Gmbh | Composição farmacêutica com efeito anticonvulsivo sinergístico |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| US8450336B2 (en) * | 2006-12-14 | 2013-05-28 | Nps Pharmaceuticals, Inc | Use of D-serine derivatives for the treatment of anxiety disorders |
| US7747551B2 (en) * | 2007-02-21 | 2010-06-29 | Neurovista Corporation | Reduction of classification error rates and monitoring system using an artificial class |
| US8933065B2 (en) * | 2008-04-01 | 2015-01-13 | The University Of North Carolina At Chapel Hill | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| US20110281808A1 (en) * | 2010-05-14 | 2011-11-17 | Allmax Nutrition Inc. | Composition and Method for Increasing Pre Workout Thermogenics |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| EP2646001A2 (en) | 2010-12-02 | 2013-10-09 | UCB Pharma GmbH | Formulation of lacosamide |
| WO2018031748A1 (en) * | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378729A (en) * | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| US6277825B1 (en) * | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| US6197764B1 (en) * | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| ATE301995T1 (de) * | 2000-08-17 | 2005-09-15 | Teva Pharma | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE60127459T2 (de) * | 2000-08-25 | 2007-07-12 | Research Corp. Technologies, Inc., Tucson | Verwendung von aminosäurehaltigen Antikonvulsiva zur Behandlung von Schmerz |
| ES2307671T3 (es) | 2000-11-21 | 2008-12-01 | Ucb Pharma, S.A. | Compuestos de gaba n-alquilados, procedimientos para su preparacion y su uso como medicamentos. |
| US20040116505A1 (en) * | 2001-02-23 | 2004-06-17 | Gregory Krauss | Treatment of tics, tremors and related disorders |
| PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| ES2185606T3 (es) | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6828462B2 (en) * | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| EP1539145A2 (en) * | 2002-09-13 | 2005-06-15 | Eisai Co., Ltd. | Method of treating tremors |
| AU2003283160A1 (en) | 2002-11-18 | 2004-06-15 | Bradley J. Steeves | Shrew paralytic peptide for use in neuromuscular therapy |
| US20050227961A1 (en) * | 2004-04-08 | 2005-10-13 | Vela Pharmaceuticals, Inc. | Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| EP1604654A1 (en) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604656A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
-
2005
- 2005-06-10 US US11/149,181 patent/US7427601B2/en not_active Expired - Fee Related
- 2005-06-22 EA EA200700108A patent/EA013592B1/ru not_active IP Right Cessation
- 2005-06-22 KR KR1020067025264A patent/KR20070034477A/ko not_active Abandoned
- 2005-06-22 CA CA2566301A patent/CA2566301C/en not_active Expired - Fee Related
- 2005-06-22 WO PCT/EP2005/006750 patent/WO2006000397A1/en not_active Ceased
- 2005-06-22 BR BRPI0512622-3A patent/BRPI0512622A/pt not_active IP Right Cessation
- 2005-06-22 UA UAA200613472A patent/UA88166C2/ru unknown
- 2005-06-22 NZ NZ551207A patent/NZ551207A/en not_active IP Right Cessation
- 2005-06-22 CN CN2005800185331A patent/CN1964733B/zh not_active Expired - Fee Related
- 2005-06-22 AU AU2005256468A patent/AU2005256468B2/en not_active Ceased
- 2005-06-22 JP JP2007517196A patent/JP5038892B2/ja not_active Expired - Fee Related
- 2005-06-22 EP EP05753740A patent/EP1758606A1/en not_active Withdrawn
- 2005-06-22 MX MXPA06015010A patent/MXPA06015010A/es active IP Right Grant
- 2005-06-23 TW TW094121028A patent/TWI361693B/zh not_active IP Right Cessation
- 2005-06-24 MY MYPI20052909A patent/MY146509A/en unknown
- 2005-06-24 AR ARP050102604A patent/AR049940A1/es not_active Application Discontinuation
-
2006
- 2006-10-30 ZA ZA200609021A patent/ZA200609021B/xx unknown
- 2006-11-30 IL IL179732A patent/IL179732A0/en unknown
-
2007
- 2007-01-23 NO NO20070423A patent/NO20070423L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MY146509A (en) | 2012-08-15 |
| CN1964733B (zh) | 2012-05-23 |
| NZ551207A (en) | 2010-07-30 |
| JP2008503533A (ja) | 2008-02-07 |
| AU2005256468A1 (en) | 2006-01-05 |
| IL179732A0 (en) | 2007-05-15 |
| TWI361693B (en) | 2012-04-11 |
| CA2566301A1 (en) | 2006-01-05 |
| CN1964733A (zh) | 2007-05-16 |
| EA200700108A1 (ru) | 2007-06-29 |
| EA013592B1 (ru) | 2010-06-30 |
| US7427601B2 (en) | 2008-09-23 |
| JP5038892B2 (ja) | 2012-10-03 |
| EP1758606A1 (en) | 2007-03-07 |
| KR20070034477A (ko) | 2007-03-28 |
| AU2005256468B2 (en) | 2010-12-09 |
| US20050288234A1 (en) | 2005-12-29 |
| UA88166C2 (ru) | 2009-09-25 |
| BRPI0512622A (pt) | 2008-03-25 |
| TW200603823A (en) | 2006-02-01 |
| WO2006000397A1 (en) | 2006-01-05 |
| NO20070423L (no) | 2007-03-22 |
| MXPA06015010A (es) | 2007-03-26 |
| ZA200609021B (en) | 2008-04-30 |
| CA2566301C (en) | 2011-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049940A1 (es) | Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor | |
| AR056467A1 (es) | USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR | |
| AR061475A1 (es) | Compuestos peptidicos para tratar status epilepticus refractario | |
| AR061743A1 (es) | Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro | |
| AR061476A1 (es) | Composicion farmaceutica con efecto anticonvulsivo sinergico | |
| AR050612A1 (es) | Novedoso uso de compuestos peptidos para tratar dolor por cancer de huesos, dolor inducido por quimioterapia y nucleosidos y composicion farmaceutica | |
| Maes et al. | Two hands, one brain, and aging | |
| AR112414A1 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos | |
| PA8456901A1 (es) | 2-aminopiridinas que contienen sustituyentes de anillos condensados | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| AR050970A1 (es) | Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih; composiciones farmaceuticas que las contienen y uso de las mismas como medicamentos. | |
| AR100770A1 (es) | Uso de oxadiazoles sustituidos para combatir hongos fitopatogénicos | |
| CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
| DE602007010781D1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
| AR029185A1 (es) | Derivado de naftiridina | |
| Luksik et al. | The role of immune checkpoint inhibition in the treatment of brain tumors | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| AR085285A1 (es) | Metodos para tratar enfermedades de la retina | |
| EA201690719A1 (ru) | Композиции гербицидов и защитных средств, содержащие амиды n-(1,3,4-оксадиазол-2-ил)арилкарбоновой кислоты | |
| TR200103351T2 (tr) | Nos inhibitörleri için yeni farmasötik kombinasyonlar. | |
| AR050098A1 (es) | Uso de compuestos peptidicos para tratar dolor en la neuralgia trigeminal | |
| ECSP19077740A (es) | Compuesto de n-(4-piridil)nicotinamida o sal del mismo | |
| AR050096A1 (es) | Uso de compuestos peptidicos para tratar disquinesia | |
| AR050196A1 (es) | Uso de compuestos peptidicos para tratar esclerosis lateral amiotrofica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |